

IN THE CLAIMS: See Listing of Claims. This listing will replace all prior versions of claims in the application.

REMARKS

The Applicants acknowledge the Examiner's comprehensive Office Action with appreciation. Claims 29-42 remain pending in the application. The Office indicates that Claims 29-37 are allowable. The Office raises rejections under 35 USC § 112, first and second paragraphs.

Claims 38-42 are rejected for lack of enablement under 35 USC § 112, first paragraph. It is the position of the Office that the specification, while being enabling for specific compounds as hypolipaeamic agents, does not reasonably provide enablement for the breadth of compounds encompassed by instant Formula (I) and for the various disorders recited in Claims 38-42.

With this Response, the Applicants provide a Declaration by Dr. Sylvain RAULT, a scientist skilled in this particular art, which speaks to the enablement rejection. Specifically, the Declarant provides pharmacological data for a representative compound of the invention which demonstrates that the instant compounds exhibit Src kinase activity. Moreover, the Declarant also provides literature references which demonstrate that one skilled in the art would recognize that compounds which exhibit Src kinase activity have a definite and positive utility in the treatment of cancer.

Therefore, since treatment of hyperlipidaemia is acknowledged as enabled by the Office, and treatment of cancer is supported by the RAULT Declaration, Claim 38 has been amended to limit the conditions claimed to be treatable to cancer and hyperlipidaemia, and Claims 39, 41, and 42 have been cancelled. Thus, the Applicants submit that the instant invention is enabled with respect to the treatment of the conditions claimed. Reconsideration and withdrawal of the lack of enablement rejection is respectfully requested.